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Recent studies demonstrate that bisphosphonates suppress bone resorption by leading to apoptosis of the osteoclast and inhibiting the differentiation
to mature osteoclasts. The influence of bisphosphonates on bone formation is unknown, although it has been hypothesized that bisphosphonates inhibit
osteoblast apoptosis and stimulate osteoblast proliferation and differentiation in vitro, leading to increased bone formation. The purpose of this studywas
to investigate the effect of bisphosphonates on bone formation. We administered risedronate at 0.05, 0.5 or 5.0 μg/kg/day or alendronate at 0.1, 1.0 or
10 μg/kg/day subcutaneously for 17 days to 6-month-old female Sprague–Dawley rats. Control rats were given a daily subcutaneous injection of saline.
Following sacrifice, the femoral and tibial mid-diaphyses were harvested and mineralizing surface (MS/BS), mineral apposition rate (MAR) and bone
formation rate (BFR/BS) were measured on periosteal and endocortical surfaces. In the femur, periosteal MAR was significantly lower in all treatment
groups (22–29% for risedronate, 26–36% for alendronate) than in control. In the tibia, periosteal MAR and BFR of all treatment groups were
significantly lower (41–50% for risedronate, 43–52% for alendronate) than in the control group. Because the periosteal surfaces of these bones are only
undergoing bone formation in modeling mode, our results show that bisphosphonates suppress bone formation independently of bone resorption.
Because this effect is seen on periosteal MAR rather than on periosteal MS/BS, we hypothesize that bisphosphonates affect the activity of individual
osteoblasts at the cell level. This may help to explain the reason that the anabolic effects of teriparatide are blunted when administered concurrently with
or following a course of bisphosphonates in humans.
© 2006 Elsevier Inc. All rights reserved.Keywords: Rodent; Modeling and remodeling; Osteoblast; Bone histomorphometryIntroduction
The nitrogen-containing bisphosphonates, alendronate and ri-
sedronate, suppress bone turnover, increase bone mass (primarily
through increases in mineralization) and reduce fracture risk in
osteoporotic women [5,6,8,17,31,39]. They act by promoting os-
teoclast apoptosis and inhibiting differentiation to mature os-
teoclasts [16,25,30,32,40,41] or by reducing osteoclast activity
[2,10,11,15,31,38,40,44], either through an inhibition of farnesyl
diphosphonate synthase (FPP) in the mevalonate pathway, or by
otherwise inhibiting prenylation of small GTPases. The influence
of bisphosphonates on bone formation is unknown, although it has
been hypothesized, based primarily on studies in culture, that
bisphosphonates inhibit osteoblast apoptosis [1,35,38] and may⁎ Corresponding author.
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doi:10.1016/j.bone.2006.05.006stimulate osteoblast proliferation and differentiation [18,19,23,
26,41,42], leading to increased bone formation.
Studies in animal models have produced equivocal results. In
ovariectomized rats, risedronate had no effect on tibial periosteal
surface apposition, and suppressed bone formation on the tibial
endosteal surface [2,43]. In intact growing rats, on the other hand,
alendronate significantly suppressed mineral apposition rate and
bone formation rate on the periosteal surface of the tibia [3].
Furthermore in OPG knock-out mice, risedronate markedly sup-
pressed both periosteal and endocortical mineral apposition rate
[33]. These data suggest that bisphosphonates may suppress bone
formation independently of bone resorption.
Specific effects of bisphosphonates on osteoblast activity
and bone formation are difficult to test on remodeling
surfaces where resorption and formation are coupled because
suppression of bone turnover naturally reduces both bone
resorption and bone formation. However, the periosteal
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resorption but rather is known to undergo direct bone
apposition in modeling mode. Based on data from the
literature that suggested that bisphosphonates inhibit osteo-
blast apoptosis, we hypothesized that bisphosphonates would
enhance periosteal bone formation. We tested this hypothesis
by evaluating the effects of risedronate and alendronate on
bone formation on periosteal surfaces known to be
undergoing modeling formation in adult rats.
Materials and methods
Six-month-old female Sprague–Dawley rats (n = 62) (Harlan, Indianapolis,
IN, USA) were housed two per cage at Indiana University's Laboratory Animal
Resource Center. Animal rooms were environmentally controlled at a temp-
erature of 67–77°F and a relative humidity of 30–70%. A light cycle of 12 h
light and 12 h dark maintained. Water and standard rat feed were provided ad
libitum during the acclimation and experimental periods. All procedures were
approved by Indiana University's Institutional Animal Care and Use Committee.
Rats were divided by weight into 7 groups. Control rats (CNT; n = 9) were
given a daily subcutaneous (sc) injection of saline vehicle. Six groups of rats
were injected subcutaneously daily for 17 days with risedronate (RIS) in a saline
carrier at a dose of 0.05 μg/kg per day (RIS-low; n = 9), 0.5 μg/kg per day (RIS-
mid; n = 9) or 5 μg/kg per day (RIS-high; n = 9); or alendronate (ALN) at a dose
of 0.1 μg/kg per day (ALN-low; n = 9), 1.0 μg/kg per day (ALN-mid; n = 8) or
10 μg/kg per day (ALN-high; n = 9). The middle doses are equivalent to the
therapeutic dose used clinically. Drug dosages were designed for dose equi-
valence based on the relative potency of risedronate and alendronate.
All rats were given an intraperitoneal (ip) injection of calcein (10 mg/kg
body mass; Sigma Chemical Co., St. Louis, MO, USA) on days 8 and 3 prior toFig. 1. Effects of bisphosphonate treatment on femur diaphyseal bone surface. (A) Pe
***P b 0.05 vs. RIS-low.killing. The right femurs and tibias were removed and cleaned of soft tissue. The
diaphyses were dehydrated in graded alcohols, cleared in xylene and embedded
in methylmethacrylate. Using a diamond-embedded wire saw (Histo-saw; Dela-
ware Diamond Knives, Wilmington, DE, USA), transverse thick sections
(70 μm) were removed from the middle of the diaphyses and mounted unstained
on standard microscope slides. Histomorphometric parameters were measured at
100× magnification from two slides per limb on a Nikon Optiphot fluorescence
microscope (Nikon, Inc., Garden City, NY, USA) using the Bioquant digitizing
system (R&M Biometrics, Nashville, TN, USA). Total bone perimeter (B.Pm),
single-label perimeter (sL.Pm) and double-label perimeter (dL.Pm) were
measured on periosteal and endocortical surfaces at 100× magnification.
Double-label area (dL.Ar) was collected at 200× magnification. Primary data
were averaged for calculation of the derived parameters: mineralizing surface
(MS/bone surface [BS] = [1/2 sL.Pm + dL.Pm]/B.Pm; %); mineral apposition
rate (MAR = dL.Ar/dL.Pm per 5 days; μm/day); and bone formation rate (BFR/
BS =MAR ×MS/BS × 3.65; μm3/μm2/year). Terminology is in accordance with
the American Society for Bone and Mineral Research (ASBMR) committee on
histomorphometric nomenclature [34]. Statistical tests were performed using
SAS software (SAS Institute, Inc.). Differences among treatment groups were
evaluated using a one-way analysis of variance (ANOVA). When a significant
overall F value ( P b 0.05) was present, differences between individual group
means were tested using Fisher's protected least-significant difference (PLSD)
post hoc test. For all tests, P b 0.05 was considered statistically significant. Data
are presented as mean ± standard deviation.
Results
There was a significant reduction in mineral apposition rate
on the periosteal surfaces of both the femur and tibia at all doses
of both bisphosphonates. On the femoral periosteal surface, this
reduction ranged from 21% to 29% for risedronate and betweenriosteal surface, (B) endosteal surface. *P b 0.05 vs. CNT, **P b 0.01 vs. CNT,
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periosteal surface, the reduction was slightly greater than in the
femur, ranging from 41% to 50% for risedronate and 43% to 52%
for alendronate (Figs. 2 and 3B). For the tibial periosteal surface,
but not for the femoral periosteal surface, this translated into a
significant depression of bone formation rate. There were no
significant differences between bisphosphonate-treated groups.
On endocortical surfaces, significant suppression compared to
control animals was found only in bone formation rate in the
femur (Fig. 1). This suppression ranged between 61% and 67%.
No significant differences among groups were found for femoral
MS/BS or MAR on the endocortical surface, nor were any signif-
icant differences found on the endocortical surface of the tibia
(Fig. 2). Again, no significant differences were found between
risedronate and alendronate-treated groups.
Discussion
Our data show that the bisphosphonates at clinical dose levels
as well as lower levels significantly suppress bone formation
independent of that found from coupled bone remodeling. This
suppression was primarily found for mineral apposition rate,
which is generally considered as an indicator of individual cell-
level activity. No significant suppression was found for mineral-
izing surface, suggesting that bisphosphonates may not have a
suppressive effect on osteoblast proliferation or differentiation but
rather only on the individual activity of osteoblasts.Fig. 2. Effects of bisphosphonates treatment on tibia diaphyseal bone surfaIt is not certain whether the bisphosphonates suppress osteo-
blast activity through direct action on the osteoblast itself, or only
indirectly through osteoclast regulation of osteoblast activity.
Several studies show in vitro a direct effect of bisphosphonates on
osteoblast proliferation and differentiation, independent of any
effects that may occur through suppression of bone resorption.
However, these studies differ on exactly how bisphosphonates
may affect these cell-level processes, showing either an inhibitory
effect on both proliferation and differentiation [27], a stimulatory
effect [18,19,23,26,42], a stimulatory effect on differentiation, but
a suppressive effect on proliferation [37], or no effect on either
[20]. It is well known that osteoclasts ingest large amounts of
bisphosphonates released from resorbed bonematrix, and that this
prevents protein prenylation necessary for their proper function
[10,11]. Direct effects of bisphosphonates on non-resorbing cells,
including osteoblasts in culture, have been reported [12], although
this apparently conflicts with data from the same group that
suggests that risedronate, at least, is not internalized by osteoblasts
[13]. Even if osteoblasts do internalize bisphosphonate, they do
not internalize much [12] and because bisphosphonates cannot be
metabolized by the osteoblast their intracellular concentration
could increase over time. It is still possible that even a small
amount of drug could interfere with cell function. Indeed, Gasser
et al. [21] observed that bisphosphonates are able to prevent
protein prenylation in osteoblasts.
Osteoprotegerin (OPG) production in osteoblasts, which is
stimulated by bisphosphonates [41], also has a function in auto-ce. (A) Periosteal surface, (B) endosteal surface. *P b 0.01 vs. CNT.
Fig. 3. Periosteal surface from cross section of diaphysis. (A) Femur, original magnification: ×100. (B) Tibia, original magnification: ×200.
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showed that mineral apposition rate was significantly increased
in OPG knock-out mice, but that this elevation of MAR was
decreased in OPG−/− when risedronate was administered at
0.01 mg/kg/day for 30 days. This suppression of osteoblast
function occurred without any change in the RANKL–RANK
interaction. They also observed that risedronate treatment al-tered osteoblast shape from more cuboidal, typical of an active
osteoblast, to flatter, more typical of a lining cell or a quiescent
osteoblast. They suggest that osteoclasts regulate osteoblast
function directly. This regulation could occur even at a remote
site not undergoing coupled remodeling.
These results may in part explain why the anabolic effects of
teriparatide are blunted by concurrent [4,15] or prior [14]
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the attenuation of teriparatide effects by bisphosphonates is that as
bone formation is reduced as a consequence of lower activation
frequency, there are fewer mature osteoblasts available for teripa-
ratide to stimulate [28]. We offer the alternative explanation that
bisphosphonates impair the activity of individual cells and make
them less receptive to stimulation by teriparatide. We found no
evidence of a suppressive effect of alendronate on bone's mineral-
izing surface (MS/BS), which would be indicative of fewer avail-
able fully differentiated osteoblasts, but only an effect to suppress
mineral apposition rate. This is consistent with the observation of
Gasser et al. [22] who showed reduced MAR in rats pre-treated
with alendronate and then subsequently treatedwith PTH.Gasser et
al. suggested that this blunting effect could occur through a direct
effect on the lining cells, which do not convert to active osteoblasts
because of the inhibitory effect of bisphosphonates on cytoskeletal
function. This explanation coincides nicely with the observation of
Nakamura et al. [33] that risedronate caused de-differentiation of
active osteoblasts to flatter cells more typical of lining cells. Gasser
et al, however, also showed that a two-month alendronate with-
drawal period to allow washout of the drug prior to the initiation of
PTH treatment did not restore the normal anabolic response to PTH.
This suggests that there is also a recurring suppression of bone
formation caused by continuing interaction of matrix embedded
drug on the lining cells or active osteoblasts. This matrix interaction
effect could still occur through direct influence on the osteoblast,
independent of the effect on the portion of bone formation that
occurs as the result of coupled remodeling.
It is known that there is an “anabolic window” following the
initiation of teriparatide therapy. This is caused by an uncoupling
of resorption and formation that allows formation to occur through
direct apposition of bone to trabecular and periosteal surfaces
[24,29] 3–4 months before the rise in coupled remodeling [7].
This may be one reason that teriparatide treatment following pre-
treatment with alendronate has its greatest attenuating effects
within the first 6 months of teriparatide treatment [14].
This effect on bone formation also may help to explain the
failure to find consistent increases in bone volume following treat-
ment with bisphosphonates [9,36]. Indeed, Boivin et al. [5] have
proposed that the prolonged period of secondarymineralization and
increased mean tissue age caused by the bisphosphonates can
account for almost all of the increased BMD observed over the first
3 years of treatment. One might expect that suppression of bone
resorption by alendronate would nevertheless allow the refilling of
the remodeling space by osteoblastic bone formation, resulting in a
3–5% increase in bone volume. However, this has been difficult to
detect from human biopsy studies [9,36]. An independent sup-
pressive effect on osteoblasts at the BMU level could account for
the absence of these changes in bone volume.
In this study, we showed that bisphosphonates suppress bone
formation on periosteal surfaces that are modeling in formation
mode. This may indicate a direct effect on osteoblast activity
and suppression of bone formation independently of bone res-
orption, but an indirect effect dependent on suppression of re-
sorption at remote sites and perhaps mediated through OPG
cannot be excluded. Regardless of which of these mechanisms
is correct, the simple observation that bisphosphonates can havea suppressive effect on bone formation provides an explanation
for the observation that the anabolic effects of teriparatide are
blunted when administered in conjunction with bisphosphonate
treatment in human patients.
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